Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanu Modi

Showing results (31-40 of 115) with videos related to

Pageof 12
Sort By:
Breast Cancer Research : BCR|March 17, 2016
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancerIan E Krop, Shanu Modi, Patricia M LoRusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumorsKomal Jhaveri, Kathy Miller, Lee Rosen, et al.
JAMA Oncology|October 14, 2021
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A ReviewPaolo Tarantino, Shanu Modi, Sara M Tolaney, et al.
Annals of Surgical Oncology|July 2, 2015
The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy RadiationT Jonathan Yang, Monica Morrow, Shanu Modi, et al.
Cancer|June 1, 2012
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancerMuralidhar Beeram, Ian E Krop, Howard A Burris, et al.
Breast Cancer Research and Treatment|April 13, 2013
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancerShanu Modi, Cristina Saura, Charles Henderson, et al.
CA: a Cancer Journal for Clinicians|November 12, 2021
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologiesPaolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2002
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancerShanu Modi, Katherine S Panageas, Elaine T Duck, et al.
NPJ Breast Cancer|October 22, 2023
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysisNelson S Moss, Jolene M Singh, Anne S Reiner, et al.
Clinical Breast Cancer|February 6, 2010
Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan resultsPatrick G Morris, Catherine Van Poznak, Shanu Modi, et al.
Pageof 12

Showing results (31-40 of 115) with videos related to

Sort By:
Pageof 12
Breast Cancer Research : BCR|March 17, 2016
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancerIan E Krop, Shanu Modi, Patricia M LoRusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumorsKomal Jhaveri, Kathy Miller, Lee Rosen, et al.
JAMA Oncology|October 14, 2021
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A ReviewPaolo Tarantino, Shanu Modi, Sara M Tolaney, et al.
Annals of Surgical Oncology|July 2, 2015
The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy RadiationT Jonathan Yang, Monica Morrow, Shanu Modi, et al.
Cancer|June 1, 2012
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancerMuralidhar Beeram, Ian E Krop, Howard A Burris, et al.
Breast Cancer Research and Treatment|April 13, 2013
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancerShanu Modi, Cristina Saura, Charles Henderson, et al.
CA: a Cancer Journal for Clinicians|November 12, 2021
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologiesPaolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2002
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancerShanu Modi, Katherine S Panageas, Elaine T Duck, et al.
NPJ Breast Cancer|October 22, 2023
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysisNelson S Moss, Jolene M Singh, Anne S Reiner, et al.
Clinical Breast Cancer|February 6, 2010
Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan resultsPatrick G Morris, Catherine Van Poznak, Shanu Modi, et al.
Pageof 12